SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-20-011442
Filing Date
2020-05-20
Accepted
2020-05-20 17:22:51
Documents
9
Period of Report
2020-05-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20200519_8k.htm 8-K 39041
2 EXHIBIT 4.1 ex_187389.htm EX-4.1 121383
3 EXHIBIT 5.1 ex_187390.htm EX-5.1 12581
4 EXHIBIT 10.1 ex_187391.htm EX-10.1 194589
5 EXHIBIT 10.2 ex_187392.htm EX-10.2 59222
6 EXHIBIT 99.1 ex_187393.htm EX-99.1 14420
7 EXHIBIT 99.2 ex_187394.htm EX-99.2 14285
8 a2.jpg GRAPHIC 25300
9 ex_187390img001.jpg GRAPHIC 2745
  Complete submission text file 0001437749-20-011442.txt   495927
Mailing Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902
Business Address 2020 AVON COURT SUITE 4 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 20899049
SIC: 2834 Pharmaceutical Preparations